Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | HTR2B | P41595 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 12/20 | 0.41 |
| ▸ | MAOA | P21397 | 11/20 | 0.41 |
| ▸ | KDM1A | O60341 | 9/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.40 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.40 |
| ▸ | HTR2C | P28335 | 2/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4356377 | 0.91 | RECQL (0.42) | CYP1A2LMNACYP3A4HTR2BTP53 | |
| SCHEMBL7774927 | 0.79 | RECQL (0.39) | CYP1A2LMNACYP3A4HTR2BTP53 | |
| SCHEMBL11320221 | 0.77 | RECQL (0.37) | CYP1A2LMNACYP3A4HTR2BTP53 | |
| SCHEMBL4193725 | 0.76 | TSHR (0.35) | CYP1A2LMNACYP3A4MAOBMAOA | |
| SCHEMBL1074533 | 0.74 | KDM1A (0.40) | CYP1A2LMNAHTR2BMAOBMAOA | |
| SCHEMBL7511837 | 0.74 | KDM1A (0.40) | HTR2BMAOBMAOAKDM1ACYP2C19 | |
| Propane SCHEMBL23045273 | 0.73 | KDM1A (0.43) | HTR2BMAOBMAOAKDM1AHTR2C | |
| Methane SCHEMBL16507862 | 0.72 | KDM1A (0.39) | HTR2BMAOBMAOAKDM1AHTR2C | |
| SCHEMBL7427186 | 0.72 | KDM1A (0.39) | LMNAHTR2BMAOBMAOAKDM1A | |
| SCHEMBL11466567 | 0.72 | EDNRA (0.47) | GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7569729-B2 | Analyzing stability of atomoxetine hydrochloride by determining pH of sample of atomoxetine hydrochloride in aqueous solution; stable atomoxetine hydrochloride contains reduced amount of free hydrogen chloride, such that an aqueous solution has a pH of 4-7; shelf life, purity; attention-deficit disorder | TEVA PHARMACEUTICAL FINE CHEMICALS S.R.L. (IT) | 2009-08-04 | — | — | US | disclosed |
| US-20080146675-A1 | Stable Atomoxetine Hydrochloride, a process for the preparation thereof, and an analytical control of its stability | CASTELLI EUGENIO | 2008-06-19 | — | — | US | disclosed |
| EP-1889828-A1 | Stable atomoxetine hydrochloride, a process for the preparation thereof, and an analytical control of its stability | Teva Pharmaceutical Fine Chemicals S.R.L. (IT) | 2008-02-20 | — | — | EP | disclosed |
| EP-1751085-A1 | STABLE ATOMOXETINE HYDROCHLORIDE, A PROCESS FOR THE PREPARATION THEREOF, AND AN ANALYTICAL CONTROL OF ITS STABILITY | Teva Pharmaceutical Fine Chemicals S.R.L. (IT) | 2007-02-14 | — | — | EP | disclosed |
| US-20060252836-A1 | Stable atomoxetine hydrochloride, a process for the preparation thereof, and an analytical control of its stability | TEVA PHARMACEUTICALS USA, INC. | 2006-11-09 | — | — | US | disclosed |
| WO-2006108120-A1 | STABLE ATOMOXETINE HYDROCHLORIDE, A PROCESS FOR THE PREPARATION THEREOF, AND AN ANALYTICAL CONTROL OF ITS STABILITY | TEVA PHARMACEUTICAL FINE CHEMICALS S.R.L. (IT) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252836-A1 | Stable atomoxetine hydrochloride, a process for the preparation thereof, and an analytical control of its stability | SLC6A4, SLC6A2, HTR5A | CYP1A2 80/4885LMNA 2710/4885CYP3A4 37/4885 |
| US-20080146675-A1 | Stable Atomoxetine Hydrochloride, a process for the preparation thereof, and an analytical control of its stability | SLC6A4, SLC6A2, HTR5A | CYP1A2 80/4885LMNA 2710/4885CYP3A4 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.